| Characteristics . | Value . |
|---|---|
| Age, y, median (IQR) | 47 (40–53) |
| Female, n (%) | 205 (41) |
| Marital status, n (%) | |
| Not married | 18 (3) |
| Married | 318 (64) |
| Domestic partnership | 10 (2) |
| Separated | 39 (8) |
| Divorced | 8 (2) |
| Widowed | 107 (21) |
| Education level, n (%) | |
| No schooling | 56 (11) |
| Primary | 254 (51) |
| Secondary | 109 (22) |
| Tertiary | 81 (16) |
| Years on ART, median (IQR) | 9 (6–12) |
| ART regimen prior to TLD, n (%) | |
| 3TC/TDF/EFV | 222 (44) |
| 3TC/AZT/NVP | 193 (39) |
| Other | 85 (17) |
| Characteristics . | Value . |
|---|---|
| Age, y, median (IQR) | 47 (40–53) |
| Female, n (%) | 205 (41) |
| Marital status, n (%) | |
| Not married | 18 (3) |
| Married | 318 (64) |
| Domestic partnership | 10 (2) |
| Separated | 39 (8) |
| Divorced | 8 (2) |
| Widowed | 107 (21) |
| Education level, n (%) | |
| No schooling | 56 (11) |
| Primary | 254 (51) |
| Secondary | 109 (22) |
| Tertiary | 81 (16) |
| Years on ART, median (IQR) | 9 (6–12) |
| ART regimen prior to TLD, n (%) | |
| 3TC/TDF/EFV | 222 (44) |
| 3TC/AZT/NVP | 193 (39) |
| Other | 85 (17) |
Abbreviations: 3TC, lamivudine; ART, antiretroviral therapy; AZT, zidovudine; EFV, efavirenz; IQR, interquartile range; NVP, nevirapine; TDF, tenofovir; TLD, tenofovir/lamivudine/dolutegravir.
| Characteristics . | Value . |
|---|---|
| Age, y, median (IQR) | 47 (40–53) |
| Female, n (%) | 205 (41) |
| Marital status, n (%) | |
| Not married | 18 (3) |
| Married | 318 (64) |
| Domestic partnership | 10 (2) |
| Separated | 39 (8) |
| Divorced | 8 (2) |
| Widowed | 107 (21) |
| Education level, n (%) | |
| No schooling | 56 (11) |
| Primary | 254 (51) |
| Secondary | 109 (22) |
| Tertiary | 81 (16) |
| Years on ART, median (IQR) | 9 (6–12) |
| ART regimen prior to TLD, n (%) | |
| 3TC/TDF/EFV | 222 (44) |
| 3TC/AZT/NVP | 193 (39) |
| Other | 85 (17) |
| Characteristics . | Value . |
|---|---|
| Age, y, median (IQR) | 47 (40–53) |
| Female, n (%) | 205 (41) |
| Marital status, n (%) | |
| Not married | 18 (3) |
| Married | 318 (64) |
| Domestic partnership | 10 (2) |
| Separated | 39 (8) |
| Divorced | 8 (2) |
| Widowed | 107 (21) |
| Education level, n (%) | |
| No schooling | 56 (11) |
| Primary | 254 (51) |
| Secondary | 109 (22) |
| Tertiary | 81 (16) |
| Years on ART, median (IQR) | 9 (6–12) |
| ART regimen prior to TLD, n (%) | |
| 3TC/TDF/EFV | 222 (44) |
| 3TC/AZT/NVP | 193 (39) |
| Other | 85 (17) |
Abbreviations: 3TC, lamivudine; ART, antiretroviral therapy; AZT, zidovudine; EFV, efavirenz; IQR, interquartile range; NVP, nevirapine; TDF, tenofovir; TLD, tenofovir/lamivudine/dolutegravir.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
